gateman, Thanks for that. I am still learning like everybody esle here. but have done a bit more thinking about this, thats the great thing about posting it forces us to think carefully.
This is still ealrly stage science but having 4 Big Pharma on board isa bigeffort, it validates the science way beyond our capabilities, it still has a long way to go, but to get these guys on board is a very big tick at this point.
NW has copped a pasting on HC regarding his credibility, my discreet inquiries tell me he is a man of high integrity and very competant. PYC is a great team from what I can find out.
I dont think the science here is overly difficult or expensive to commercialise. Inlike RNAI for difficulty or Monoclonal Antibodies for expense. That may be two attractions for partners.
Where PYC is way in front of most, is the money, most BIOs flounder because they cant raise money, or are out there for years witheir begging bowl after Phase 2. PYC has locked in the development costs up front as well as secured ongoing revenues and company funding. That is GOLD.
If more announcements and expanded deals do land as indictaed this will likely turned into one very exciting investment. every single one of these companies has hit at least one big hurdle on the way. 2011 was PYCs tough one.
PYC Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)